Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter (X-TRA)

This study has been completed.
Janssen Research & Development, LLC
Information provided by (Responsible Party):
Bayer Identifier:
First received: April 22, 2013
Last updated: July 22, 2016
Last verified: December 2015